ECMO support may be associated with improved survival in tuberculosis associated severe ARDS.

IF 2.6 3区 医学 Q2 RESPIRATORY SYSTEM BMC Pulmonary Medicine Pub Date : 2024-10-24 DOI:10.1186/s12890-024-03356-4
Bahar Nalbant, Alix Buhlmann, Lennart Wild, Christian Bode, Sascha David, Benjamin Seeliger, Klaus Stahl
{"title":"ECMO support may be associated with improved survival in tuberculosis associated severe ARDS.","authors":"Bahar Nalbant, Alix Buhlmann, Lennart Wild, Christian Bode, Sascha David, Benjamin Seeliger, Klaus Stahl","doi":"10.1186/s12890-024-03356-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Data describing outcome of extracorporeal membrane oxygenation (ECMO) support in Tuberculosis (Tbc)-associated acute respiratory distress syndrome (ARDS) remain sparce and are mostly confined to singular case reports. The aim of this case series was to analyze intensive care unit (ICU) survival in patients with Tbc-associated ARDS receiving veno-venous (vv-) ECMO support and to compare those to patients not receiving ECMO.</p><p><strong>Case presentation: </strong>ICU survival was analyzed retrospectively in 14 patients treated for Tbc-associated ARDS at three ECMO-referral university hospitals (Hannover Medical School, University Hospital Bonn (both Germany) and University Hospital Zurich (Switzerland)) during the last 14 years, of which eight patients received additional vv-ECMO support and six standard care only. ICU survival was significantly higher in patients receiving additional vv-ECMO support (62.5%, n = 5/8) compared to those that did not (16.7%, n = 1/6) (p = 0.021). ECMO support was associated with reduced ICU mortality (Hazard ratio adjusted for baseline SOFA score [adj. HR] 0.125 (95% confidence interval (CI): 0.023-0.689), p = 0.017). Median (IQR) time on ECMO and invasive ventilation in the vv-ECMO group were 20 (11-26) and 37 (27-53) days, respectively. Major bleeding defined as transfusion requirement of 4 units of blood or more or surgical and/or radiologic intervention occurred only in one patient, in whom pulmonary bleeding was fatal. Thromboembolic events occurred in none of the vv-ECMO patients.</p><p><strong>Discussion and conclusions: </strong>This retrospective analysis from three large ECMO centers with similar SOPs suggests vv-ECMO support as a feasible approach in patients with severe Tbc-associated ARDS. Although affiliated with extended runtimes, vv-ECMO might be associated with improved survival in those patients. Vv-ECMO support should thus be considered in Tbc-associated ARDS to enable lung protective strategies during prolonged lung recovery.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"24 1","pages":"530"},"PeriodicalIF":2.6000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515833/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12890-024-03356-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Data describing outcome of extracorporeal membrane oxygenation (ECMO) support in Tuberculosis (Tbc)-associated acute respiratory distress syndrome (ARDS) remain sparce and are mostly confined to singular case reports. The aim of this case series was to analyze intensive care unit (ICU) survival in patients with Tbc-associated ARDS receiving veno-venous (vv-) ECMO support and to compare those to patients not receiving ECMO.

Case presentation: ICU survival was analyzed retrospectively in 14 patients treated for Tbc-associated ARDS at three ECMO-referral university hospitals (Hannover Medical School, University Hospital Bonn (both Germany) and University Hospital Zurich (Switzerland)) during the last 14 years, of which eight patients received additional vv-ECMO support and six standard care only. ICU survival was significantly higher in patients receiving additional vv-ECMO support (62.5%, n = 5/8) compared to those that did not (16.7%, n = 1/6) (p = 0.021). ECMO support was associated with reduced ICU mortality (Hazard ratio adjusted for baseline SOFA score [adj. HR] 0.125 (95% confidence interval (CI): 0.023-0.689), p = 0.017). Median (IQR) time on ECMO and invasive ventilation in the vv-ECMO group were 20 (11-26) and 37 (27-53) days, respectively. Major bleeding defined as transfusion requirement of 4 units of blood or more or surgical and/or radiologic intervention occurred only in one patient, in whom pulmonary bleeding was fatal. Thromboembolic events occurred in none of the vv-ECMO patients.

Discussion and conclusions: This retrospective analysis from three large ECMO centers with similar SOPs suggests vv-ECMO support as a feasible approach in patients with severe Tbc-associated ARDS. Although affiliated with extended runtimes, vv-ECMO might be associated with improved survival in those patients. Vv-ECMO support should thus be considered in Tbc-associated ARDS to enable lung protective strategies during prolonged lung recovery.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ECMO 支持可提高结核病相关重症 ARDS 患者的存活率。
背景:描述体外膜氧合(ECMO)支持治疗结核病(Tbc)相关急性呼吸窘迫综合征(ARDS)疗效的数据仍然很少,且大多局限于单个病例报告。本病例系列旨在分析接受静脉-静脉(vv-)ECMO 支持的结核病相关 ARDS 患者的重症监护室(ICU)存活率,并与未接受 ECMO 支持的患者进行比较:我们对过去 14 年中在三家 ECMO 转诊大学医院(汉诺威医学院、波恩大学医院(德国)和苏黎世大学医院(瑞士))接受治疗的 14 名 Tbc 相关 ARDS 患者的 ICU 存活率进行了回顾性分析,其中 8 名患者接受了额外的 vv-ECMO 支持,6 名患者仅接受了标准护理。与未接受支持的患者(16.7%,n = 1/6)相比,接受额外的 vv-ECMO 支持的患者 ICU 存活率明显更高(62.5%,n = 5/8)(p = 0.021)。ECMO 支持与 ICU 死亡率降低相关(根据基线 SOFA 评分调整的危险比 [adj. HR] 为 0.125(95% 置信区间 (CI):0.023-0.689),p = 0.017)。vv-ECMO 组 ECMO 和有创通气时间的中位数(IQR)分别为 20 天(11-26 天)和 37 天(27-53 天)。仅有一名患者发生大出血,即需要输血 4 个单位或更多,或需要手术和/或放射介入治疗,该患者的肺出血是致命性的。没有一名vv-ECMO患者发生血栓栓塞事件:这项来自三个大型 ECMO 中心的回顾性分析表明,在严重 Tbc 相关 ARDS 患者中,vv-ECMO 支持是一种可行的方法。尽管vv-ECMO需要延长运行时间,但可能与这些患者存活率的提高有关。因此,Tbc相关性ARDS患者应考虑采用Vv-ECMO支持,以便在肺恢复期延长期间采取肺保护策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Pulmonary Medicine
BMC Pulmonary Medicine RESPIRATORY SYSTEM-
CiteScore
4.40
自引率
3.20%
发文量
423
审稿时长
6-12 weeks
期刊介绍: BMC Pulmonary Medicine is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
期刊最新文献
Predicting solitary pulmonary lesions in breast cancer patients using 18fluorodeoxyglucose-positron emission tomography/computed tomography combined with clinicopathological characteristics. Assessment of novel cardiovascular biomarkers in chronic obstructive pulmonary disease. Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA-IIIB non-small-cell lung cancer in real-world practice. Development of a predictive nomogram for early identification of pulmonary embolism in hospitalized patients: a retrospective cohort study. A nomogram for predicting lymphovascular invasion in lung adenocarcinoma: a retrospective study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1